| Literature DB >> 35424604 |
Xue Xiao1, Shujun Zhen2.
Abstract
Fluorescence anisotropy/polarization is an attractive and versatile technique based on molecular rotation in biochemical/biophysical systems. Traditional fluorescence anisotropy/polarization assays showed relatively low sensitivity for molecule detection, because widespread molecular masses are too small to produce detectable changes in fluorescence anisotropy/polarization value. In this review, we discuss in detail how the potential of fluorescence anisotropy/polarization signal approach considerably expanded through the implementation of mass amplification, recycle the target amplification, fluorescence probes structure-switching amplification, resonance energy transfer amplification, and provide perspectives at future directions and applications. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35424604 PMCID: PMC8982260 DOI: 10.1039/d2ra00058j
Source DB: PubMed Journal: RSC Adv ISSN: 2046-2069 Impact factor: 3.361
Fig. 1Proposed representation of the local segmental motion of dye contributed (arrow) to the variation of the FA signal in relation to the aptamer probe structure. rf is the FA in the absence of analyte. Reprinted with permission from ref. 26. Copyright (2010) Elsevier.
Fig. 2Working principle of protein amplifying FA for sensitive detection of small molecules. Reprinted with permission from ref. 28. Copyright (2012) American Chemical Society.
Fig. 3Schematic illustration of the strategy of Hg2+ ion detection using FP enhancement by AuNPs. Reprinted with permission from ref. 65. Copyright (2008) Wiley.
Fig. 4Principle of the dual amplified aptasensor based on bivalent aptamers and Ag10NPs enhancement. Reprinted with permission from ref. 68. Copyright (2017) American Chemical Society.
Fig. 5A schematic representation of ssDNA detection using a novel GO amplified FA assay. Reprinted with permission from ref. 9. Copyright (2015) Royal Society of Chemistry.
Fig. 6(A) Synthesis procedure for the functionalized streptavidin–SiO2NPs. (B) A working principle of the proposed FP biosensor for HBV DNA detection. Reprinted with permission from ref. 85. Copyright (2015) Royal Society of Chemistry.
Fig. 7The concept and the principle of MIL-101 amplified fluorescence anisotropy strategy for HIV-DNA detection. Reprinted with permission from ref. 32. Copyright (2014) Royal Society of Chemistry.
Fig. 8Illustration of a chimeric aptamers-based and MoS2 nanosheet-enhanced label-free FP strategy for ATP detection. Reprinted with permission from ref. 94. Copyright (2018) American Chemical Society.
Fig. 9Target assisted Exonuclease III-catalyzed amplification FP for DNA detection. Reprinted with permission from ref. 34. Copyright (2011) Royal Society of Chemistry.
Fig. 10Schematic illustration of enzyme-free FA assay for miRNA-21 detection. Reprinted with permission from ref. 83. Copyright (2017) American Chemical Society.
Fig. 11Schematic illustration of the QD FP enhancement homogenous system based on K+-mediated G-quadruplex formation for the determination of Hg2+ and biothiols. Reprinted with permission from ref. 103. Copyright (2014) Royal Society of Chemistry.
Fig. 12Schematic of competitive aptamer FA assay for the determination of OTA with signal-on responses in a binding buffer that contains a 0.1% Tween 20. Reprinted with permission from ref. 110. Copyright (2020) American Chemical Society.
List of targets currently detected by FA/FP
| Targets | Amplification technique | Signal mechanisms | Dynamic ranges | Detection limit | Samples | Ref. |
|---|---|---|---|---|---|---|
| Adenosine | GO amplification | Mass change-based | 60–400 μM | 22 μM | — |
|
| Adenosine | Single-stranded DNA binding protein enhancer | Mass change-based | 2–50 μM | 1 μM | Human serum |
|
| Adenosine | Phosphodiesterase I and protein amplification | Mass change-based | 0.5–1000 μM | 500 nM | Cell media |
|
| Adenosine | GO, nicking enzyme dual amplification | Mass change-based | 4 pM to 10 μM | 2.0 pM | — |
|
| Adenosine | Oligonucleotide amplification | Segmental motion change-based | 0–6 μM | ∼1 μM | — |
|
| ATP | HCR, protein dual amplification | Mass change-based | 0.2–20 μM | 100 nM | Cell media, human urine, human serum |
|
| ATP | Protein amplification | Mass change-based | 1–25 μM | 0.5 μM | Cell media |
|
| ATP | GO amplification | Mass change-based | 0.5–250 μM | 100 nM | Human serum |
|
| ATP | Digoxin antibody amplification | Mass change-based | 10–350 μM | 3.7 μM | Serum |
|
| ATP | Protein, proximity effect amplification | Mass change-based, segmental motion change-based | 0.5–500 μM | 0.5 μM | Human urine |
|
| ATP | SiO2NPs enhancement | Mass change-based | 40 pM to 100 μM | 20 pM | — |
|
| ATP | MoS2 nanosheet | Mass change-based | 0.3–40 μM | 34.4 nM | Human urine |
|
| ATP | DNA nanosheet amplification | Mass change-based | 150–450 μM | 43 μM | — |
|
| Thrombin | GO amplification | Mass change-based | 0.5–4 mg L−1 | 0.19 mg L−1 | — |
|
| Thrombin | GO, nicking enzyme dual amplification | Mass change-based | 2 fM to 200 nM | 1 fM | Human plasma |
|
| Thrombin | TiS2 nanosheet, Exo I amplification | Mass change-based | 0.05 pM to 100 nM | 0.01 pM | Human serum |
|
| Thrombin | CSDA and PS NP enhancement | Mass change-based | 50 aM to 100 pM | 28 aM | Human plasma |
|
| ssDNA | GO amplification | Mass change-based | 8–40 nM | 4.6 nM | — |
|
| ssDNA | AuNPs amplification | Mass change-based | — | 0.95 nM | — |
|
| ssDNA | MOF amplification | Mass change-based | 0.3–12 nM | 0.2 nM | — |
|
| ssDNA | Exo III amplification | Mass change-based | 0.1 fM to 1 nM | 83 aM | — |
|
| ssDNA | AuNPs amplification | Mass change-based | 150 pM to 6 nM | 73 pM | Serum |
|
| ssDNA | AuNPs, NSET dual amplification | Fluorescence lifetime-based, mass change-based | — | 372 pM | DMEM |
|
| ssDNA | GO, T7 Exo-assisted amplification | Mass change-based | 50–2000 pM | 38.6 pM | Human serum |
|
| ssDNA | SiO2NPs amplification | Mass change-based | 1–800 nM | 0.65 nM | Human serum |
|
| ssDNA | HCR and SiO2NPs amplification | Mass change-based | 0–2.5 nM | 34 pM | Human serum |
|
| ssDNA | MOF amplification | Mass change-based | 1–20 nM | 1 nM | — |
|
| ssDNA | DNA nanosheet amplification | Mass change-based | 10–50 nM | 8 nM | — |
|
| miRNA | Protein amplification | Mass change-based | 10 pM to 10 nM | 8.5 pM | Cell lysis buffer, cell lysate |
|
| miRNA | GO and CHA amplification | Mass change-based | 0–16 nM | 47 pM | Cell extractions |
|
| miRNA | T7 Exo, polystyrene nanospheres amplification | Mass change-based | 0.001–10 nM | 0.001 nM | Human serum, cell extractions |
|
| Hg2+ | AuNPs amplification | Mass change-based | 1 nM to 1 mM | 1 nM | River water |
|
| Hg2+ | AgNPs amplification | Mass change-based | 10–400 nM | 6.6 nM | Tap water |
|
| Hg2+ | MOF amplification | Mass change-based | 20–200 nM | 8.66 nM | Tap water |
|
| Hg2+ | K+-mediated G-quadruplex enhancement | Mass change-based | 10–800 nM | 8.6 nM | Lake water |
|
| Cu2+ | GO and DNAzyme amplification | Mass change-based | 1–32 nM | 1 nM | — |
|
| Cu2+ | DNAzyme self-assembled AuNPs amplification | Mass change-based | 0.001–10 μM | ∼1 nM | River water |
|
| Cu2+ | DNAzyme self-assembled gold nanorods amplification | Mass change-based | 8–320 pM | 8.40 pM | — |
|
| Cu2+ | SiO2 NPs amplification | Mass change-based | 0.050–2.0 μM | 0.0178 μM | River water |
|
| Pb2+ | Multiple G bases amplification | Fluorescence lifetime-based | 200 pM to 100 nM | 100 pM | — |
|
| Pb2+ | Phosphate-perylene modification G-quadruplex probes amplification | Segmental motion change-based | 25–5000 nM | 24.5 nM | Tap water |
|
| Pb2+ | Cleavable DNA–protein hybrid molecular beacon amplification | Mass change-based, segmental motion change-based | 1–20 nM | 0.5 nM | Water samples |
|
| Pb2+ | DNAzyme self-assembled AuNPs amplification | Mass change-based | 0.001–10 μM | 1 nM | River water |
|
| Ag+ | AuNPs amplification | Mass change-based | 50–750 nM | 9.5 nM | Tap water |
|
| Ag+ | MnO2 nanosheet amplification | Mass change-based | 30–240 nM | 9.1 nM | Tap water, lake water |
|
| Cocaine | Protein amplification | Mass change-based | 1–100 μM | 0.8 μM | Human urine |
|
| Cocaine | Protein, isothermal exponential amplification | Mass change-based | 30 pM to 30 μM | 18 pM | Human serum |
|
| Aflatoxin B1 | Protein, proximity effect amplification | Mass change-based, segmental motion change-based | 60 pM to 125 nM | 60 pM | White wine |
|
| Aflatoxin B1 | GO amplification | Mass change-based | 0.05–5 nM | 0.05 nM | Rice extract |
|
| Aflatoxin B1 | Protein, isothermal exponential amplification | Mass change-based | 0.4 pM to 400 nM | 0.24 pM | — |
|
| Ochratoxin A | Protein amplification | Mass change-based | — | 3.6 nM | White wine |
|
| Ochratoxin A | Protein, proximity effect amplification | Mass change-based, segmental motion change-based | 1 nM to 5 μM | 1 nM | White wine |
|
| Cysteine | AgNPs amplification | Mass change-based | 20–700 nM | 11 nM | — |
|
| Cysteine | K+-mediated G-quadruplex enhancement | Mass change-based | 50–2000 nM | 9.9 nM | Human urine |
|
| Ricin B-chain | GO, Exo III-assisted amplification | Mass change-based | 1–13.3 μg mL−1 | 400 ng mL−1 | Orange juice |
|
| K+ | GO amplification | Mass change-based | 10 μM to 2 mM | 1 μM | — |
|
| DNA–protein interactions | Protein amplification | Mass change-based | — | 6.3 nM | — |
|
| Chloramphenicol | PCR and protein amplification | Mass change-based | 0.001–200 nM | 0.5 pM | Honey |
|
| EcoRI endonuclease | AuNPs amplification | Mass change-based | 5.0 × 10−4 to 10 U mL−1 | 5.0 × 10−4 U mL−1 | — |
|
| Lac | MEF, Ag10NPs amplification | Mass change-based, fluorescence lifetime-based | 0.2 ng mL−1 to 25 μg mL−1 | 1.25 pM | Milk powder |
|
| DNA MTase activity | Carbon nanotube signal amplification | Mass change-based | — | 1.0 × 10−4 U mL−1 | Human serum |
|
| Apyrase | Carbon nanoparticle amplification | Mass change-based | 0.1–0.5 U μL−1 | 0.05 U μL−1 | — |
|
| Lipopolysaccharides ( | GO amplification | Mass change-based | — | 38.7 ng mL−1 | Sodium chloride injection |
|
| I− | MOF amplification | Mass change-based | 0.02–3.0 μM | 17.4 nM | Tap water |
|
| PSA | MOG amplification | Mass change-based | 0.5–8 ng mL−1 | 0.33 ng mL−1 | Human serum |
|
| Folate receptor | TiS2 nanosheet, exo I amplification | Mass change-based | 0.01–20 ng mL−1 | 0.003 ng mL−1 | Human serum |
|
| DNA glycosylase activity | WS2 nanosheet and exo III amplification | Mass change-based | 0.00080–0.40 U mL−1 | ∼0.00030 U mL−1 | Cell extracts |
|